A handful of researchers can hold years of R&D value in their heads and on their screens: proprietary formulas, clinical trial results, genetic sequences, manufacturing processes.
That concentration of value is also what makes the pharmaceutical industry so exposed, especially once that IP starts moving between CROs, academic partners, and manufacturing collaborators as a normal part of doing business.
External attacks get the headlines. But the real risk often starts inside the organization, and most of it isn't malicious. It's a researcher pasting sensitive data into a generative AI tool to save time, or a departing scientist taking files they've worked on for years without thinking twice.
This blog examines:
- The scale of insider threats in pharma and biotechnology.
- What the costs are when risks aren't managed.
- The steps you can take to mitigate those risks.
What causes insider risk in pharma and biotech?
The structure of R&D in pharmaceutical companies is what creates exposure to insider risk.
Proprietary formulas, trial data, genetic data, and manufacturing processes pass through a relatively small number of hands, and those hands don't stay inside one company. Sensitive information moves constantly to CROs running trials, academic partners collaborating on early research, and manufacturing partners scaling production.
The openness that makes research and development possible also makes security breaches more likely.
And most of the risk exposure doesn't come from anyone trying to cause harm.
Industry data estimates up to 95% of insider intellectual property theft results from human error, such as a misdirected file, a personal device used for convenience, or a shortcut around an approved process. The person responsible for a data breach is usually a well-meaning employee rather than a corporate spy.
A newer version of this unintentional risk is seen when researchers paste proprietary data into generative AI tools to speed up legitimate work, without realizing that, in doing so, they've moved sensitive material outside the company's control.
What is the cost of ignoring insider risk for pharma companies?
When data loss is intentional, the damage tends to be severe.
Between 2011 and 2016, GSK scientist Yu Xue and several associates stole cancer-research trade secrets, using them to help build a biotech startup. Federal prosecutors later valued the stolen trade secrets at between $550 million and over $1 billion.
In 2017, Merck was hit by the NotPetya cyberattack, which cost the company several hundred million dollars in damages and disrupted vaccine and drug production for weeks. It's one of the clearest examples of how quickly a single incident can turn into a company-wide problem, in an industry where production delays don't just cost revenue.
The impact of insider risk in biotech and pharma is felt across:
- R&D loss: Trial data or a formulation can represent years of work and significant capital. When it's lost, there's no way to recover the time already spent developing it, and often no way to recreate it on the same timeline even with the funding to try.
- Competitive loss: Pharma and biotech firms run on being the first to make a breakthrough. If a rival reaches market with a similar compound first, patent timing and market position can shift permanently, no matter how strong the underlying science was on either side.
- Regulatory exposure: Trial and patient data fall under the GDPR as a "special category" and carry HIPAA-adjacent obligations in the US. A leak involving that kind of data brings potential fines and enforcement action, plus the cost of the investigation itself, which can run long after the original incident is resolved.
- Trust and partnership cost: Pharma and biotech depend on partnerships: CROs, academic collaborators, and investors all need to trust in a company's data protection measures. An organization that's failed at insider risk management risks damaging or losing those relationships.
- Patient impact: Supply disruption or delayed trials don't come with a price tag the way the other categories do, but they're specific to this industry in a way they aren't for most others. A delay here can mean a treatment reaching patients months or years later than it should have.
In pharma data security, time is of the essence. Costs and repercussions escalate if insider incidents aren't caught quickly.
How do you mitigate insider risk in pharma and biotech?
Managing insider risk isn't about having zero incidents. It's about reducing how often incidents occur and speeding up incident response efforts.
That depends on three things:
- Who has access.
- How people are trained.
- How activity is analyzed.
1. Vet and control access
New employees, contractors, and visiting researchers all need rigorous screening, but that same scrutiny should apply whenever someone is granted access to a new dataset or a new trial phase. Roles and responsibilities change, and access should be reviewed whenever they do.
The safest default is least-privilege access: a lab researcher should be able to see what their role requires and nothing more. Commercial strategy documents or regulatory filings aren't relevant to their work, so there's no reason for them to have access.
Access also needs tightening at the two moments it changes most: when someone joins and when someone leaves.
New hires should get access provisioned in stages, tied to what they need in their first weeks, rather than full access from day one.
Departing staff need the opposite: access revoked immediately on their last day, not queued for the next IT cleanup cycle. Leavers account for a disproportionate share of exfiltrated data, whether they mean to take it or not.
2. Build a security-conscious culture
Ongoing, scenario-based training does more than a single onboarding compliance module, especially when it's built around situations that people recognize, such as a phishing email disguised as a request from a CRO or a shortcut through a tool that hasn't been approved.
Much of the pharma and biotech workforce comes from research and academic backgrounds rather than corporate security ones, so you must tailor your cybersecurity training to speak to that audience.
Also, reporting speed matters as much as the training itself.
That means a clear, low-friction way to report a mistake the moment it happens: a direct line to IT and security teams (not a form buried three menus deep) plus a stated policy that flagging a mistake quickly won't lead to disciplinary action on its own.
When people trust that disclosing early won't cost them, a small slip has a much better chance of staying that way.
3. Analyze behavior with context, not blanket rules
Behavioral analytics that can tell the difference between normal cross-team collaboration and a genuine anomaly is how you catch the incidents that matter.
That analysis needs to cover every channel IP moves through, including web and network activity, file transfers, cloud uploads, USB devices, email, and unauthorized AI tools.
When introducing a data loss prevention tool to your staff, position it as protection for their work, rather than oversight of their activities. This minimizes resistance.
Why is Teramind ideal for securing pharma biotech innovation?
Because up to 95% of insider risk stems from unintentional human error or workflow shortcuts, security can't rely on rigid legacy DLP or intrusive blanket oversight tools. Life science organizations need lightweight, contextual protection that safeguards multi-million-dollar R&D assets without stalling scientific discovery.
Here is how Teramind secures pharmaceutical and biotechnology companies against insider risk across the entire research lifecycle:
Unified single-agent architecture
Instead of stacking fragmented point solutions that create software bloat and slow down compute-heavy bioinformatics workstations or 3D molecular modeling pipelines, Teramind consolidates endpoint Data Loss Prevention (DLP), User and Entity Behavior Analytics (UEBA), and workforce analytics into a single software agent.
Security teams gain complete operational visibility with minimal endpoint footprint and zero performance latency.
360-degree visibility across 15+ channels
Proprietary formulas and trial data constantly move across organizational boundaries to CROs, academic collaborators, and contract manufacturers.
Teramind delivers 360-degree coverage across more than 15 system channels (including web applications, cloud storage, USB drives, email, instant messaging, social media, local print jobs, network traffic, and command-line terminals), ensuring no data movement path is left uncovered.
User and Entity Behavior Analytics (UEBA)
Rather than relying on static, known-bad signatures, Teramind's behavioral baselining learns each user's normal activity patterns over time to detect genuine anomalies.
It flags subtle risks, such as a researcher accessing clinical trial files outside their normal scope or a sudden surge in data movement prior to an employee's departure, catching both careless slips and deliberate data exfiltration.
Patented Optical Character Recognition (OCR)
High-value life science IP isn't always neatly saved as labeled text files. Teramind's patented OCR engine scans, indexes, and analyzes visual text embedded directly within live screens, video recordings, and images.
Whether a user takes a screenshot of a molecular compound, opens a scanned lab notebook page, or views an image of a genetic sequence, OCR reads the visual content on screen and enforces protection policies instantly.
Proactive intervention
When a policy breach occurs, reactive logging isn't enough.
Teramind's pharma biotech DLP acts in real-time to prevent data loss before it happens. It can issue instant coaching warnings to guide well-meaning researchers, block unauthorized file transfers, or lock compromised endpoint sessions as suspicious activity unfolds.
Shadow AI detection and generative AI DLP
Generative AI tools introduce rapid risk exposure when scientists paste proprietary code, trial outcomes, or chemical structures into public generative AI assistants to draft papers faster.
Teramind delivers endpoint-centric GenAI DLP, inspecting clipboard actions, AI prompt inputs, and file uploads in real-time to block unapproved data sharing before it leaves your environment.
Forensic session playback and evidentiary chain-of-custody
Text-based event logs rarely tell the whole story during an IP breach investigation.
Teramind captures high-definition video recordings synchronized with system activity logs, providing a legally admissible, chain-of-custody visual record. Security, HR, and legal teams can replay exact user sessions to verify context, accelerate incident response, and conclusively determine intent.
Audit-ready regulatory compliance and privacy controls
Operating under HIPAA, GDPR, SOC 2, and GxP frameworks requires a delicate balance between security and compliance liability.
Teramind produces immutable audit trails for regulatory bodies while enforcing granular privacy controls (such as dynamic sensitive data masking on screen recordings), ensuring data sovereignty and protecting employee trust.
Try Teramind's Free Live Demo | Start Your Free Trial Today
FAQs
How do you balance insider risk visibility with research culture and employee privacy?
The primary friction when introducing user activity analytics to high-performing scientists and PhDs is the perception of intrusive oversight. Researchers require autonomy, and heavy-handed oversight can stifle innovation or trigger distrust.
Teramind resolves this tension by focusing on contextual risk rather than blanket oversight. Administrators can configure granular privacy rules, such as disabling screen recording on personal/non-work applications, anonymizing user data, and masking sensitive PII/PHI.
By positioning data loss prevention as an automated safety net that protects the integrity of their R&D from human error or external attribution, security teams can maintain institutional trust while safeguarding high-value IP.
Can Teramind help mitigate insider risk when collaborating with external CROs and academic partners?
Yes. Pharmaceutical innovation relies on sending proprietary formulas, genetic sequences, and clinical data across organizational boundaries to Contract Research Organizations (CROs), university labs, and joint ventures. This extended ecosystem creates significant insider risk exposure.
Teramind provides visibility into data moving across external touchpoints by inspecting cloud uploads, web portal transfers, email attachments, USB devices, and remote desktop sessions.
Through Role-Based Access Control (RBAC) and vendor risk policies, you can enforce least-privilege access for temporary contractors and third-party researchers, ensuring they only interact with data relevant to their specific phase of the project.
How does Teramind stop proprietary formulas or trial data from leaking into generative AI tools?
Generative AI tools and Shadow AI pose a growing insider risk in biotech. Well-meaning researchers often paste complex molecular structures, proprietary source code, or clinical trial outcomes into public generative AI assistants to draft papers or summarize findings faster.
Teramind prevents unintended exposure through real-time generative AI DLP and patented Optical Character Recognition (OCR). The platform inspects clipboard activity, on-screen text, and AI prompt inputs.
When a user attempts to paste a proprietary genetic sequence or regex-defined chemical formula into an unauthorized AI interface, Teramind automatically blocks the transfer and alerts the user to policy guidelines before data leaves the environment.
Will installing an endpoint agent slow down high-performance bioinformatics workstations?
No. Biotech and pharma environments rely on compute-heavy applications for genomic sequencing, 3D molecular modeling, and massive dataset analysis. A sluggish endpoint agent that causes latency or crashes specialized software is unacceptable to R&D teams.
Teramind's endpoint agent operates with a minimal system footprint, consuming negligible CPU and RAM resources.
Furthermore, security engineers can build custom inspection profiles that exclude resource-intensive local processes, directories, or specialized lab software rendering pipelines from heavy inspection while maintaining continuous DLP audit coverage over file transfers, network traffic, and export channels.
Is Teramind compliant with HIPAA, GDPR, and GxP standards when recording screen activity?
Yes. Capturing endpoint activity in regulated life science environments raises concerns about creating secondary regulatory liability under HIPAA, GDPR, or GxP guidelines.
Teramind is engineered to simplify regulatory compliance rather than complicate it:
- Data privacy: Automated rules can obscure or redact Protected Health Information (PHI) and Personally Identifiable Information (PII) on-screen to ensure compliance with HIPAA and GDPR "special category" data rules.
- Access controls and encryption: Video logs and audit records are encrypted in transit and at rest, accessible only by authorized security personnel through multi-factor authentication and strict RBAC.
- Tamper-proof audit trails: Teramind maintains immutable log data and visual session replays required for regulatory audits, internal investigations, and SOC 2 readiness.
Can Teramind be deployed in air-gapped or on-premises biotech manufacturing facilities?
Yes. Biomanufacturing facilities and specialized lab cleanrooms often operate under strict air-gapped network configurations to prevent cyberattacks and ensure operational continuity.
Teramind offers flexible deployment options, including SaaS, Private Cloud (AWS/Azure), and fully on-premises enterprise deployments.
For air-gapped or strictly controlled GxP environments, the On-Premise architecture allows your security team to retain 100% data sovereignty, running behavioral analytics and DLP enforcement locally without requiring external internet connectivity.
